Nebivolol, compared with classical β-blockers, exerts a high selectivity for β-adrenergic
receptors and also reduces peripheral vascular resistance by modulating nitric oxide (NO) …

Abstract β-adrenergic blocking agents, a pharmacologically diverse class of cardiovascular
medications, are recommended as first-line treatment for patients with hypertension and …

Nebivolol is a vasodilating β-blocker, which can be distinguished from other β-blockers by its
haemodynamic profile. It combines β-adrenergic blocking activity with a vasodilating effect …

Nebivolol is a novel beta1-blocker with a greater degree of selectivity for beta1-adrenergic
receptors than other agents in this class and a nitric oxide (NO)-potentiating, vasodilatory …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Endothelial dysfunction is a systemic pathological state of the endothelium characterized by
a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired …

Nebivolol is a third-generation β-adrenergic receptor antagonist (β-blocker) with high
selectivity for β 1-adrenergic receptors. In addition, it causes vasodilatation via interaction …

Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated
through the activation of the l-arginine/nitric oxide pathway. Short-term randomized clinical …

Abstract β-Adrenoceptor antagonists (β-blockers) have historically been considered an
effective and safe option for first-line treatment of hypertension. However, very recently, it …

Nebivolol is a new selective β1-adrenergic blocking agent, that possesses a peculiar
pharmacodynamic profile and an original chemical structure, by which it differs from …